Log in

Relevant bibliographies by topics / Antineoplastika / Journal articles

To see the other types of publications on this topic, follow the link: Antineoplastika.

Journal articles on the topic 'Antineoplastika'

Author: Grafiati

Published: 28 June 2021

Last updated: 29 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Antineoplastika.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Kreutzberger, Alfred, and Elfriede Kreutzberger. "Antineoplastika, 15. Mitt. Butylderivate der 5-Aminomethylenbarbitursäure." Archiv der Pharmazie 318, no. 9 (1985): 821–24. http://dx.doi.org/10.1002/ardp.19853180910.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Kreutzberger, Alfred, and Michael Sellheim. "Antineoplastika XVI [1]. 4-Alkyl-6-trifluormethyl-2-ureidopyrimidine." Journal of Fluorine Chemistry 27, no. 2 (1985): 203–12. http://dx.doi.org/10.1016/s0022-1139(00)84989-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Kreutzberger, Alfred, Peter Langner, and Jörg Stratmann. "Antineoplastika, 19. Mitt.: Darstellung vonN-[2-Chlor-4-diethylamino-(1,3,5-triazin-6-yl)]-aminosäuren." Archiv der Pharmazie 323, no. 12 (1990): 995–96. http://dx.doi.org/10.1002/ardp.19903231211.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Kreutzberger, Alfred, Peter Langner, and Jörg Stratmann. "Antineoplastika, 17. Mitt.1): Darstellung mono- und disubstituierter 2,4-Dichlor-6-diethylamino-1,3,5-triazine." Archiv der Pharmazie 324, no. 3 (1991): 173–76. http://dx.doi.org/10.1002/ardp.19913240308.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Kopjar, Nevenka, Davor Želježić, Vilena Kašuba, and Ružica Rozgaj. "Antineoplastic Drugs as a Potential Risk Factor in Occupational Settings: Mechanisms of Action at the Cell Level, Genotoxic Effects, and Their Detection Using Different Biomarkers." Archives of Industrial Hygiene and Toxicology 61, no. 1 (2010): 121–46. http://dx.doi.org/10.2478/10004-1254-61-2010-2025.

Full text

Abstract:

Antineoplastični Lijekovi Kao Čimbenik Rizika u Radnom Okolišu: Mehanizmi Djelovanja na Razini Stanice i Pregled Metoda za Otkrivanje Njihovih Genotoksičnih UčinakaU članku je prikazana osnovna podjela antineoplastičnih lijekova prema mehanizmima djelovanja na razini stanice. Objašnjeni su mehanizmi genotoksičnosti najvažnijih vrsta lijekova koji se primjenjuju u okviru uobičajenih protokola za liječenje zloćudnih novotvorina. Navedena je važeća klasifikacija antineoplastika prema kancerogenom potencijalu, podaci o mutagenom potencijalu te je prikazana njihova podjela u skladu s anatomsko-tera

APA, Harvard, Vancouver, ISO, and other styles

6

Burgaz, S., B. Karahalil, Z. Canli, et al. "Assessment of genotoxic damage in nurses occupationally exposed to antineoplastics by the analysis of chromosomal aberrations." Human & Experimental Toxicology 21, no. 3 (2002): 129–35. http://dx.doi.org/10.1191/0960327102ht230oa.

Full text

Abstract:

To estimate the genotoxic risk of occupational exposure to antineoplastic drugs, chromosomal aberration (CAs) frequencies in peripheral lymphocytes were determined for 20 nurses handling antineoplastics and 18 referents matched for age and sex. Urinary cyclophosphamide (CP) excretion rates, which are used as a marker for drug handling, were also measured on these nurses. We have observed significant frequencies of CAs (about 2.5-fold increase) including chromatid breaks, gaps, and acentric fragments for nurses handling antineoplastics as compared to control subjects (p<0.05, p<0.01, excl

APA, Harvard, Vancouver, ISO, and other styles

7

Birken, Sarah A., Alexandra Peluso, Cheyenne Wagi, et al. "Continued outpatient oncology care for cancer survivors by antineoplastic medication use: Identifying opportunities for stratified survivorship care." Journal of Clinical Oncology 40, no. 28_suppl (2022): 226. http://dx.doi.org/10.1200/jco.2022.40.28_suppl.226.

Full text

Abstract:

226 Background: Cancer survivors may be more likely to receive preventive care services when they see both oncologists and PCPs; however, some oncology visits may not be necessary, straining limited subspecialty resources. In this study, we quantified outpatient primary and oncology care utilization in the years surrounding cancer diagnosis. We further characterized the proportion of survivors with oncology visits in the absence of ongoing antineoplastic use, as we hypothesized these survivors might be appropriate for need- and risk-stratified survivorship care, a model successful outside the

APA, Harvard, Vancouver, ISO, and other styles

8

Guan, Xiaodong, Haishaerjiang Wushouer, Mingchun Yang, et al. "Influence of government price regulation and deregulation on the price of antineoplastic medications in China: a controlled interrupted time series study." BMJ Open 9, no. 11 (2019): e031658. http://dx.doi.org/10.1136/bmjopen-2019-031658.

Full text

Abstract:

BackgroundIn October 2012, the Chinese government established maximum retail prices for specific products, including 30 antineoplastic medications. Three years later, in June 2015, the government abolished price regulation for most medications, including all antineoplastic medications. This study examined the impacts of regulation and subsequent deregulation of prices of antineoplastic medications in China.MethodsUsing hospital procurement data and an interrupted time series with comparison series design, we examined the impacts of the policy changes on relative purchase prices (Laspeyres pric

APA, Harvard, Vancouver, ISO, and other styles

9

McNabb, Lorna, Eva Metrot, Micaela Ferrington, et al. "Assessment of patient perceptions of counselling on oral antineoplastic agents by a dedicated cancer services pharmacist in an outpatient cancer clinic." PLOS ONE 19, no. 6 (2024): e0304011. http://dx.doi.org/10.1371/journal.pone.0304011.

Full text

Abstract:

Background Oral antineoplastic agents have caused a paradigm shift in cancer treatment, however, they produce many unique challenges. Although oral antineoplastics can have complex administration regimes, low adherence rates and high possibilities of drug-drug interactions, they are administered unsupervised at home. Cancer services pharmacists have the required skillsets to improve patient outcomes associated with oral antineoplastic treatment by increasing patient health literacy, improving concordance and optimising administration protocols. Aim To evaluate patients’ perceptions, experience

APA, Harvard, Vancouver, ISO, and other styles

10

Hong, Samuel J., Edward C. Li, Linda M. Matusiak, and Glen T. Schumock. "Spending on Antineoplastic Agents in the United States, 2011 to 2016." Journal of Oncology Practice 14, no. 11 (2018): e683-e691. http://dx.doi.org/10.1200/jop.18.00069.

Full text

Abstract:

Purpose: Recent cancer drug approvals are lauded as being more effective with relatively fewer adverse effects, but these treatments come with a great cost to the US health care system. There is little information on recent trends in actual antineoplastic expenditures representative of the whole US health care system or by sector. Therefore, the objective of this study was to describe antineoplastic expenditures in the United States by year and sector. Methods: This was a retrospective, cross-sectional study of IQVIA (formerly QuintilesIMS) National Sales Perspective data for the period of Jan

APA, Harvard, Vancouver, ISO, and other styles

11

Roger, Inés, Paula Montero, Antonio García, et al. "Evaluation of Antineoplastic Delayed-Type Hypersensitivity Skin Reactions In Vitro." Pharmaceuticals 15, no. 9 (2022): 1111. http://dx.doi.org/10.3390/ph15091111.

Full text

Abstract:

Delayed-type hypersensitivity (DTH) is caused by a broad number of drugs used in clinic, and antineoplastic drugs show an elevated proportion of DTH, which potentially affects the quality of life of patients. Despite the serious problem and the negative economic impact deriving from market withdrawal of such drugs and high hospitalization costs, nowadays, there are no standard validated methods in vitro or in vivo to evaluate the sensitizing potential of drugs in the preclinical phase. Enhanced predictions in preclinical safety evaluations are really important, and for that reason, the aim of

APA, Harvard, Vancouver, ISO, and other styles

12

Naveed Ahmad, Junid Naveed, Nicole Whalen, Karen Hemeon, and Joseph Grant F. Rosales. "Creation of standard work for the management of outpatient oral antineoplastic therapy." Journal of Clinical Oncology 40, no. 28_suppl (2022): 369. http://dx.doi.org/10.1200/jco.2022.40.28_suppl.369.

Full text

Abstract:

369 Background: Recently, there has been a dramatic increase in the use of oral antineoplastics for the treatment of various malignancies. The development of these agents has been so rapid that the infrastructure needed for their appropriate supervision has trailed their availability. Previously at Virginia Mason, there was no standard work established for the management of patients starting these agents and consequently there were defects noted, including delays in the medications’ delivery to the patient, lack of appropriate teaching regarding potential medication toxicities and even delayed

APA, Harvard, Vancouver, ISO, and other styles

13

Rezende, Lucas Dalvi Armond, Davi de Souza Catabriga, Karielly Gasperazzo Pansini, Mateus Gonçalves Prata dos Reis, Paula de Souza Silva Freitas, and Bruno Henrique Fiorin. "Osteometabolic changes in patients under antineoplastic treatment: scoping review." Revista Ciências em Saúde 13, no. 3 (2023): 56–65. http://dx.doi.org/10.21876/rcshci.v13i3.1442.

Full text

Abstract:

Objective: To summarize the main evidence regarding osteometabolic changes in patients undergoing antineoplastic treatment. Methods: This is a scoping review, following the methodology of the Joanna Briggs Institute, using PubMed/MedLine, Cochrane Library, LILACS, The British Library, and Google Scholar. This review is registered in the Open Science Framework. Results: Many antineoplastics affect bone architecture by reducing its density, such as selective estrogen receptor modulators, aromatase inhibitors, androgen deprivation therapy, and glucocorticoids. To avoid such outcomes, treatment an

APA, Harvard, Vancouver, ISO, and other styles

14

Haroen, Harlinda, and Indriaty Gimon. "Hubungan Jenis dan Siklus Kemoterapi dengan Derajat Neuropati pada Pasien Keganasan." Medical Scope Journal 6, no. 2 (2024): 164–71. http://dx.doi.org/10.35790/msj.v6i2.53140.

Full text

Abstract:

Abstract: Antineoplastic chemotherapy agents in cancer treatment can cause peripheral neuropathy. Antineoplastic agents associated with chemotherapy-induced peripheral neuropathy include platinum-based drugs (carboplatin, cisplatin and oxaliplatin) and taxane (paclitaxel and docetaxel). This study aimed to evaluate the relationship between the type and cycle of chemotherapy with the level of neuropathy in malignant patients at Prof. Dr. R. D. Kandou Hospital, Manado, in 2022. The results obtained 43 cancer patients aged 18-65 who underwent chemotherapy, especially drugs from the platinum group

APA, Harvard, Vancouver, ISO, and other styles

15

Olin, Jacqueline L., Olga Klibanov, Alexandre Chan, and Linda M. Spooner. "Managing Pharmacotherapy in People Living With HIV and Concomitant Malignancy." Annals of Pharmacotherapy 53, no. 8 (2019): 812–32. http://dx.doi.org/10.1177/1060028019833038.

Full text

Abstract:

Objective: To describe data with selected malignancies in people living with HIV (PLWH) and HIV in individuals affected by both conditions and to summarize drug-drug interactions (DDIs) with clinical recommendations for point-of-care review of combination therapies. Data Sources: Literature searches were performed (2005 to December 2018) in MEDLINE and EMBASE to identify studies of malignancies in PLWH in the modern era. Study Selection and Data Extraction: Article bibliographies and drug interaction databases were reviewed. Search terms included HIV, antiretroviral therapy, antineoplastic age

APA, Harvard, Vancouver, ISO, and other styles

16

Rodrigues da Silva, Gustavo Henrique, Ludmilla David de Moura, Fabíola Vieira de Carvalho, et al. "Antineoplastics Encapsulated in Nanostructured Lipid Carriers." Molecules 26, no. 22 (2021): 6929. http://dx.doi.org/10.3390/molecules26226929.

Full text

Abstract:

Ideally, antineoplastic treatment aims to selectively eradicate cancer cells without causing systemic toxicity. A great number of antineoplastic agents (AAs) are available nowadays, with well-defined therapeutic protocols. The poor bioavailability, non-selective action, high systemic toxicity, and lack of effectiveness of most AAs have stimulated the search for novel chemotherapy protocols, including technological approaches that provide drug delivery systems (DDS) for gold standard medicines. Nanostructured lipid carriers (NLC) are DDS that contain a core of solid and lipid liquids stabilised

APA, Harvard, Vancouver, ISO, and other styles

17

Diaz De Cerio, Amaya, Carmen Marfil Peña, Hernan Alberto Rodriguez Montani, Virginia Alonso de Pablo, and Maria Cruz Marron. "Reducing 30% of waiting time in the administration of antineoplastic oral drugs in patients with urological cancer." JCO Oncology Practice 19, no. 11_suppl (2023): 325. http://dx.doi.org/10.1200/op.2023.19.11_suppl.325.

Full text

Abstract:

325 Background: In order to reduce waiting time in the administration of oral antineoplastics we participated in ASCO/ECO QTP. We propose the creation of an oncology nursing office, trained to evaluate and administer oral antineoplastic medication. Methods: The waiting times of patients diagnosed with urological cancer and receiving treatment with oral antineoplastic drugs are collected, between their arrival at the hospital and the drug’s dispensation. Waiting times are calculated using a prospective qualitative analysis and we represent the data using SPC graphs such as R-Charts, process map

APA, Harvard, Vancouver, ISO, and other styles

18

Galpin, A. J., and W. E. Evans. "Therapeutic drug monitoring in cancer management." Clinical Chemistry 39, no. 11 (1993): 2419–30. http://dx.doi.org/10.1093/clinchem/39.11.2419.

Full text

Abstract:

Abstract Several anticancer drugs display characteristics that make them suitable candidates for therapeutic drug monitoring (TDM), including substantial pharmacokinetic variability and a narrow therapeutic index. However, concentration-effect relationships (pharmacodynamics) of most antineoplastic agents have not been well defined, thus limiting the widespread clinical application of TDM for cancer chemotherapy. Strategic incorporation of pharmacokinetic studies during phase I-III clinical trials should facilitate the identification of concentration-effect relationships and the definition of

APA, Harvard, Vancouver, ISO, and other styles

19

Seal, Brian S., Jianying Yao, Jonathan K. Kish, Dana Stafkey-Mailey, and Michael Eaddy. "Evaluation of national treatment trends in ovarian cancer." Journal of Clinical Oncology 32, no. 30_suppl (2014): 204. http://dx.doi.org/10.1200/jco.2014.32.30_suppl.204.

Full text

Abstract:

204 Background: Evaluate patterns of care among women diagnosed with metastatic (M) and non-metastatic (NM) ovarian cancer (OvCa). Methods: Using MarketScan Commercial/Medicare databases, women ≥18 years old with primary diagnosis of OvCa continuously enrolled ≥6 months pre- and post-index diagnosis were selected. Patients receiving chemotherapy (chemo) prior to index diagnosis were excluded. Eligible patients were stratified into NM and M cohorts and M patients into those diagnosed with M ≤90 days (M1), 91-180 days (M2) and ≥ 181 days (M3) post index diagnosis. Types of treatments, time to in

APA, Harvard, Vancouver, ISO, and other styles

20

Mertens, W. C., L. J. Cassells, D. E. Brown, et al. "Chemotherapy ordering in a computerized physician order entry (CPOE) environment: A longitudinal analysis of defects from oncologist to patient." Journal of Clinical Oncology 24, no. 18_suppl (2006): 6040. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.6040.

Full text

Abstract:

6040 Background: While published data suggest low chemotherapy error rates, the rate of chemotherapy ordering process defects and who detects them remains uncertain. Methods: Outpatient treatment plans/orders were prospectively evaluated by pharmacy prior to preparation, then by nursing prior to administration. Data collected included the nature of defects, how detected, utility of regimen-specific care sets (facilitating antineoplastic dose calculation and adjunct agent selection), and patient impact. Results: Pharmacy recognized problems with 36% of orders (comprising 1,082 cycles/4,600 drug

APA, Harvard, Vancouver, ISO, and other styles

21

Das, Swagatika, H. Inci Gul, Umashankar Das, Jan Balzarini, Stephen G. Dimmock, and Jonathan R. Dimmock. "Novel Conjugated Unsaturated Ketones with Submicromolar Potencies Towards some Leukemic and Colon Cancer Cells." Medicinal Chemistry 15, no. 4 (2019): 430–38. http://dx.doi.org/10.2174/1573406414666181015142633.

Full text

Abstract:

Background: Cancer continues to be the major health burden worldwide. There is an urgent need for the development of novel antineoplastic compounds to treat this devastating condition. Various alkylating anticancer drugs have been employed in the clinic for treating cancers. Unsaturated conjugated ketones are a group of alkylators which are of significant interest as potent antineoplastic agents. Objective: The goal of this study is to discover unsaturated conjugated ketones which are novel potent cytotoxins displaying growth-inhibitory properties towards neoplasms and also to serve as cytotox

APA, Harvard, Vancouver, ISO, and other styles

22

Bagattini, Ângela Maria, Daniela Pachito, Rafael Pacheco, Aline Rocha, and Rachel Riera. "Qualidade metodológica das avaliações econômicas de antineoplásicos submetidas à Agência Nacional de Saúde Suplementar (ANS) na atualização do rol 2020 – Estudo de avaliação crítica." Jornal Brasileiro de Economia da Saúde 13, no. 1 (2021): 31–42. http://dx.doi.org/10.21115/jbes.v13.n1.p31-42.

Full text

Abstract:

Objective: To describe and critically appraise the economic evaluations of antineoplastic drugs submitted to the ANS during the process of updating its 2020’ list of procedures. Methods: Cross-sectional study of critical analysis of the economic evaluation studies included in the documentation submitted to the ANS with the aim of incorporating them into the list of procedures. The methodological quality assessment was carried out using the Methodology Checklist 6: Economic Evaluations Version 3.0 of the Scottish Intercollegiate Guidelines Network. Results: Overall, 49 economic evaluations were

APA, Harvard, Vancouver, ISO, and other styles

23

S R, Vendra. "A Review on Venetoclax – An Antineoplastic Agent." Journal of Medical Science And clinical Research 05, no. 04 (2017): 20012–15. http://dx.doi.org/10.18535/jmscr/v5i4.45.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Stojanova, Jana, Jane E. Carland, Bridin Murnion, Vincent Seah, Jim Siderov, and Florian Lemaitre. "Therapeutic drug monitoring in oncology - What’s out there: A bibliometric evaluation on the topic." Frontiers in Oncology 12 (November 10, 2022). http://dx.doi.org/10.3389/fonc.2022.959741.

Full text

Abstract:

Pharmacological therapy is the mainstay of treatment for cancer patients. Despite wide interpatient variability in systemic drug concentrations for numerous antineoplastics, dosing based on body size remains the predominant approach. Therapeutic drug monitoring (TDM) is used for few antineoplastics in specific scenarios. We conducted a rapid bibliometric evaluation of TDM in oncology to capture a snapshot of research in this area over time and explore topics that reflect development in the field. Reports with the composite, indexed term ‘therapeutic drug monitoring’ in the title and abstract w

APA, Harvard, Vancouver, ISO, and other styles

25

Cho, Han Na, Lyn Wells, and Zachery Halford. "Implementation and Evaluation of APOTECAchemo in a Community Cancer Center: A Comparative Study of Robotic Versus Manual Antineoplastic Preparation." Journal of Pharmacy Technology, September 13, 2024. http://dx.doi.org/10.1177/87551225241278203.

Full text

Abstract:

Background: The ever-increasing complexity and demand for antineoplastic therapy necessitates innovative solutions to improve the accuracy and safety of drug preparation. Objective: To evaluate the utilization of an advanced robotic chemotherapy drug compounding system (APOTECAchemo) at a Community Cancer Center (CCC), examining accuracy, efficiency, and staff perceptions. Methods: This single-center, retrospective study evaluated the preparation of 7 intravenous (IV) antineoplastics at a CCC over a 1-year period. We compared manual methods with the APOTECAchemo system. The primary measure of

APA, Harvard, Vancouver, ISO, and other styles

26

Donkor, Kofi N., Jane S. Lee, Myrna M. Hana, and Sehyun Jeong. "Incidence and Risk Factors of Hypomagnesemia in Patients With Bone Metastasis From Solid Malignancies Treated With Denosumab: A Retrospective Chart Review." Annals of Pharmacotherapy, September 17, 2024. http://dx.doi.org/10.1177/10600280241277557.

Full text

Abstract:

Background: Hypomagnesemia is associated with poor clinical outcomes in cancer patients. Patients with bone metastasis from solid malignancies receiving denosumab (Dmab) to prevent skeletal-related events often receive concurrent antineoplastic agents for cancer treatment. The incidence and risk factors of hypomagnesemia in patients receiving Dmab and the optimal frequency of monitoring serum magnesium (Mg) levels have not been studied in these patient populations. Objective: The objective is to investigate the incidence and potential risk factors of hypomagnesemia and the optimal frequency of

APA, Harvard, Vancouver, ISO, and other styles

27

Mundi, Prabhjot S., Filemon S. Dela Cruz, Adina Grunn, et al. "A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies." Cancer Discovery, April 16, 2023. http://dx.doi.org/10.1158/2159-8290.cd-22-1020.

Full text

Abstract:

Abstract Predicting in vivo response to antineoplastics remains an elusive challenge. We performed first-of-kind evaluation of two transcriptome-based precision cancer medicine methodologies to predict tumor sensitivity to a comprehensive repertoire of clinically relevant oncology drugs, whose mechanism-of-action we experimentally assessed in cognate cell lines. We enrolled patients with histologically distinct, poor prognosis malignancies who had progressed on multiple therapies, and developed low-passage, patient-derived xenograft models that were used to validate 35 patient-specific drug pr

APA, Harvard, Vancouver, ISO, and other styles

28

Chabut, Claire, and Jean-François Bussières. "Characteristics of wipe sampling methods for antineoplastic drugs in North America: comparison of six providers." Pharmaceutical Technology in Hospital Pharmacy 5, no. 1 (2020). http://dx.doi.org/10.1515/pthp-2020-0016.

Full text

Abstract:

Abstract Objectives Several societies have published guidelines to limit the occupational exposure of workers. Several of these guidelines recommend periodic (once or twice a year) environmental monitoring of specific sites where antineoplastic drugs are prepared and administered. However, most of the guidelines provide no guidance concerning which antineoplastic drugs should be monitored, the preferred sampling sites, appropriate test methods or limits of detection. The aim of this study was to characterize providers that quantify antineoplastic drug measured on surfaces. Methods This was a c

APA, Harvard, Vancouver, ISO, and other styles

29

"Antineoplastics." Reactions Weekly 1853, no. 1 (2021): 47. http://dx.doi.org/10.1007/s40278-021-94913-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

"Antineoplastics." Reactions Weekly 1853, no. 1 (2021): 56. http://dx.doi.org/10.1007/s40278-021-94922-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

"Antineoplastics." Reactions Weekly 1853, no. 1 (2021): 51. http://dx.doi.org/10.1007/s40278-021-94917-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

"Antineoplastics." Reactions Weekly 1853, no. 1 (2021): 53. http://dx.doi.org/10.1007/s40278-021-94919-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

"Antineoplastics." Reactions Weekly 1853, no. 1 (2021): 54. http://dx.doi.org/10.1007/s40278-021-94920-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

"Antineoplastics." Reactions Weekly 1853, no. 1 (2021): 49. http://dx.doi.org/10.1007/s40278-021-94915-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

"Antineoplastics." Reactions Weekly 1853, no. 1 (2021): 52. http://dx.doi.org/10.1007/s40278-021-94918-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

"Antineoplastics." Reactions Weekly 1853, no. 1 (2021): 55. http://dx.doi.org/10.1007/s40278-021-94921-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

"Antineoplastics." Reactions Weekly 1853, no. 1 (2021): 50. http://dx.doi.org/10.1007/s40278-021-94916-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

"Antineoplastics." Reactions Weekly 1853, no. 1 (2021): 57. http://dx.doi.org/10.1007/s40278-021-94923-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

"Antineoplastics." Reactions Weekly 1853, no. 1 (2021): 58. http://dx.doi.org/10.1007/s40278-021-94924-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

"Antineoplastics." Reactions Weekly 1853, no. 1 (2021): 48. http://dx.doi.org/10.1007/s40278-021-94914-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

"Antineoplastics." Reactions Weekly 1854, no. 1 (2021): 48. http://dx.doi.org/10.1007/s40278-021-95379-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

"Antineoplastics." Reactions Weekly 1854, no. 1 (2021): 51. http://dx.doi.org/10.1007/s40278-021-95382-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

"Antineoplastics." Reactions Weekly 1854, no. 1 (2021): 43. http://dx.doi.org/10.1007/s40278-021-95374-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

"Antineoplastics." Reactions Weekly 1854, no. 1 (2021): 55. http://dx.doi.org/10.1007/s40278-021-95386-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

"Antineoplastics." Reactions Weekly 1854, no. 1 (2021): 49. http://dx.doi.org/10.1007/s40278-021-95380-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

"Antineoplastics." Reactions Weekly 1854, no. 1 (2021): 46. http://dx.doi.org/10.1007/s40278-021-95377-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

"Antineoplastics." Reactions Weekly 1854, no. 1 (2021): 50. http://dx.doi.org/10.1007/s40278-021-95381-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

"Antineoplastics." Reactions Weekly 1854, no. 1 (2021): 56. http://dx.doi.org/10.1007/s40278-021-95387-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

"Antineoplastics." Reactions Weekly 1854, no. 1 (2021): 52. http://dx.doi.org/10.1007/s40278-021-95383-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

"Antineoplastics." Reactions Weekly 1854, no. 1 (2021): 40. http://dx.doi.org/10.1007/s40278-021-95371-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!